[HTML] sciencedirect.com

[HTML][HTML] A phase II randomized trial to evaluate the long-term (12-week) efficacy and safety of OC-01 (varenicline solution) nasal spray for dry eye disease: The …

H Quiroz-Mercado, E Hernandez-Quintela, KH Chiu… - The Ocular Surface, 2022 - Elsevier
Purpose Dry eye disease is characterized by loss of tear film stability. OC-01 (varenicline
solution) is a small-molecule nicotinic acetylcholine receptor agonist administered as a …
被引用次数：35 相关文章

A phase II randomized trial to evaluate the long-term (12-week) efficacy and safety of OC-01 (varenicline solution) nasal spray for dry eye disease: The MYSTIC study

H Quiroz-Mercado, E Hernandez-Quintela… - Ocular …, 2022 - pure.johnshopkins.edu
Purpose: Dry eye disease is characterized by loss of tear film stability. OC-01 (varenicline
solution) is a small-molecule nicotinic acetylcholine receptor agonist administered as a …

A phase II randomized trial to evaluate the long-term (12-week) efficacy and safety of OC-01 (varenicline solution) nasal spray for dry eye disease: The MYSTIC study

H Quiroz-Mercado… - The ocular …, 2022 - pubmed.ncbi.nlm.nih.gov
Purpose Dry eye disease is characterized by loss of tear film stability. OC-01 (varenicline
solution) is a small-molecule nicotinic acetylcholine receptor agonist administered as a …

A phase II randomized trial to evaluate the long-term (12-week) efficacy and safety of OC-01 (varenicline solution) nasal spray for dry eye disease: The MYSTIC study.

H Quiroz-Mercado, E Hernandez-Quintela… - The Ocular …, 2021 - europepmc.org
Purpose Dry eye disease is characterized by loss of tear film stability. OC-01 (varenicline
solution) is a small-molecule nicotinic acetylcholine receptor agonist administered as a …